Objective To compare the 1‐year retention rates of anti–tumor necrosis factor α (anti‐TNFα)
medications in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and …

Background The role of co-medication with tumour necrosis factor inhibitors (TNFi) is well
established in rheumatoid arthritis and ankylosing spondylitis. In psoriatic arthritis (PsA) …

Objectives To investigate whether baseline disease activity levels and responses in patients
with rheumatoid arthritis (RA) changed during the period 2000–2010. Methods Data were …

Objective To assess the effectiveness of switching to a second tumour necrosis factor
inhibitor (TNFi) in patients with ankylosing spondylitis (AS). Methods Data were extracted …

Information concerning the effectiveness of drug therapy cannot be obtained only from
randomized contro lled clinical trials, due to limitations such as a short time frame and …

Objective To examine the effectiveness and 2-year retention rates of methotrexate (MTX) in
MTX naïve patients with psoriatic arthritis (PsA). Methods Data on 430 patients with PsA …

Background Tumour necrosis factor inhibitors (TNFi) are efficacious in patients with psoriatic
arthritis (PsA), but some patients do not respond or do not tolerate their first TNFi, and are …

Objective Rheumatoid arthritis (RA) is associated with accelerated atherosclerosis. The
reduction in cardiovascular risk that is induced by methotrexate (MTX) and anti–tumor …

Objective To examine possible associations between chronic inflammatory arthritides and
pregnancy outcomes with separate analyses of first and subsequent births before and after …

Objective. To compare fertility rates in women with RA, other chronic arthritides (OCAs) and
JIA with reference women from the general population. Methods. Each woman from a …